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LeﬂunomideAbstract Objective: To assess the serum B-cell activating factor belonging to the tumor necrosis
factor family (BAFF) level in rheumatoid arthritis (RA) patients in view of different treatment
regimens received and evaluate its relation with disease activity.
Patients and methods: Ninety female RA patients were included. Sixty were on disease modifying
anti-rheumatic drugs (DMARDs); 34 on hydroxychloroquine (HCQ) plus methotrexate (MTX), 26
on leﬂunomide (LFN) plus MTX and 30 newly diagnosed cases not yet on any treatment. Thirty
age and gender matched healthy subjects served as controls. Full history taking, clinical examina-
tion and relevant laboratory investigations were performed. Disease activity score, in 28 joints
(DAS-28), was calculated.
Results: Serum BAFF level was signiﬁcantly higher in patients (1.82 ± 0.91 ng/ml) compared to
control (0.71 ± 0.33 ng/ml; p< 0.001). There was a signiﬁcantly lower BAFF and disease activity
in patients receiving DMARDs (1.55 ± 0.73 ng/ml and 3.08 ± 0.73) compared to new cases
(2.36 ± 1.02 ng/ml and 3.46 ± 0.82) (p< 0.001 and p= 0.036, respectively). Those receiving
HCQ+MTX had a lower BAFF level (1.29 ± 0.51 ng/ml) compared to those receiving
38 A.A. Mahdy et al.LFN+MTX (1.94 ± 0.85 ng/ml; p= 0.002). The BAFF level signiﬁcantly correlated with the
presence of anti-CCP antibodies, DAS28 and MTX dose in all RA patients (r= 0.24, p= 0.02;
r= 0.504, p< 0.001; r= 0.51, p< 0.001, respectively). Only DAS28 and MTX dose would highly
inﬂuence the BAFF level (p= 0.015 and p= 0.001, respectively).
Conclusion: Elevated level of BAFF in RA has been conﬁrmed with a notable relation to disease
activity making it a promising marker. The beneﬁcial effect of hydroxychloroquine in dampening
BAFF level throws light on the importance of considering it in combination among the newly devel-
oped biologics that also target B-cells.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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Rheumatoid arthritis (RA) is a chronic inﬂammatory rheumatic
disease, in which autoantibodies are part of the early disease
manifestations. A pathogenic involvement of B cells is impli-
cated inRA.1 It is a systemic autoimmune arthritis that clinically
manifests as joint pain, stiffness and swelling. If left untreated,
persistent synovitis can progress to cartilage and bone destruc-
tion; ultimately tomajor long-termdisability andmortality.Dis-
ease-modifying antirheumatic drugs (DMARDs), such as
methotrexate (MTX), leﬂunomide (LFN) and hydroxychloro-
quine (HCQ), have markedly improved clinical symptoms and
slowed joint damage. Despite their effectiveness, some patients
continue to have clinical manifestations and progressive joint
destruction. Advances in the understanding of the pathogenesis
of RA have led to the identiﬁcation of novel cellular and molec-
ular therapeutic targets. Biologic agents aimed at these targets
have provided some evidence of effectiveness that is transform-
ing the management of RA.2 Current strategic regimens which
concentrate on systematic ways to bring patients into remission
all include MTX as the ﬁrst choice.3
Although the speciﬁc trigger of the autoimmune response in
RA is not known, pathogenesis is generally believed to be asso-
ciated with the generation of autoantibodies through interac-
tions of antigen-presenting cells with the adaptive immune
system (T and B cells). The main inﬂammatory mediators of
joint inﬂammation and destruction in RA are tumor necrosis
factor alpha (TNF-a), interleukin-1 (IL-1), IL-6, chemokines,
and proteases.2 Interest in B-cells has been revived due to the
description of new functions. Supporting a role for B-cells in
the genesis of autoimmune diseases is the fact that theB-cell acti-
vating factor of the TNF ligand family (BAFF) is essential in
their physiology. Based on experiments in mice, and validated
in humans, this new cytokine has been highlighted. Excessive
production of BAFF alters immune tolerance by rescuing self-
binding B-cells. Overexpression in mice leads to autoimmune
manifestation, and BAFF levels are elevated in the serum of
autoimmune patients.4 Since BAFF has been identiﬁed as a crit-
ical and major regulatory factor for B cell maturation and sur-
vival, convincing evidence indicates that deregulation of
BAFF is involved in the pathogenesis of B-cell related autoim-
mune diseases including RA,5–7 Juvenile idiopathic arthritis
(JIA),8 SLE,9,10 Systemic sclerosis (SSc)10 and Behcets disease.11
Blockade of BAFFactivity signiﬁcantly improves the symptoms
of autoimmune diseases such as systemic lupus erythematosus
(SLE) and RA both in animal models and clinical trials.5 Ad-
vances in our understanding of the BAFF system offer the
opportunity to improve our therapeutic approach.4During the past century, many immunosuppressive drugs
have been described. Often their mechanisms of action were
established long after their discovery.12 Advances in our
understanding of the key cells and inﬂammatory cytokines
have led to the development of targeted biologic agents.2 Bio-
logic therapies have profoundly changed the course of RA, but
factors that predict response, which could be used to optimize
the use and selection of these costly agents that have poten-
tially severe side effects, have not been identiﬁed. Because B-
cells play critical roles in RA, developing serum biomarkers
of B cell activation are potential predictive factors for the efﬁ-
cacy of biologic agents targeting B cells.13
Themanagement ofRAhas entered anewerawith the arrival
of biologic agents. However, the tools needed to predict re-
sponse to these drugs to allow tailoring of the treatment regi-
mens are still lacking. This apparent gap in knowledge may
lead to the serial use of several immunosuppressive drugs, which
may expose patients to an elevated risk of adverse side effects.13
Biologic agents are effective in reducing clinical signs of
inﬂammation in RA patients who have failed DMARDs and
signiﬁcant beneﬁts of their combination with MTX have been
documented. All biologic agents carry an increased risk of
infections with an additional potential side effect of site reac-
tions. Patients being considered for biologic agents should be
screened annually for tuberculosis and should receive pneumo-
coccal, inﬂuenza, and hepatitis B vaccinations.2
Methotrexate (MTX) is currently the most frequently used
drug in the treatment of RA. The drug had been synthesized in
1948 and ﬁrst tests to treat patients with psoriasis and RA were
published in 1951. However, until the 1980s there was only
limited use of MTX in the treatment of RA. Since the 1990s
MTX is the DMARDs of ﬁrst choice for the treatment of
RA in most countries worldwide. By deﬁnition, DMARDs in
RA are those compounds for which an inhibiting effect on
radiographic progression has been demonstrated. Several com-
binations of DMARDs have been tested, most commonly with
MTX as the anchor drug. There are now three main combina-
tions that are playing an important role: MTX+HCQ,
MTX+ LFN and MTX+ biologics such as anti-TNF and
other new compounds which block IL6 receptor or T-cell acti-
vation and delete B cells.3 Emerging data from further studies
provide critical insight regarding the role of B cells and auto-
antibodies in various autoimmune conditions and will guide
the development of more efﬁcacious therapeutics and better
patient selection.14
The aim of the present study is to assess the serum BAFF
level in RA patients in view of different treatment regimens
received and evaluate its relation with the disease activity.
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2.1. Study design
Ninety female patients with deﬁnite RA diagnosed according
to the 2010 ACR/EULAR RA classiﬁcation criteria15 were
recruited from the Rheumatology and Internal medicine
outpatient clinics of Cairo University Hospitals and included
in this study. Patients on a stable dose of combination therapy
for the preceding 6 months were grouped into 34 on HCQ
(400 mg/day) + weekly intramuscular (IM) MTX and 26 on
LFN (20 mg/day) + weekly IMMTX. Thirty newly diagnosed
female RA cases not yet on any basic therapy were included
and 30 age and gender matched healthy subjects served as con-
trols. Full history taking and thorough clinical examination
were performed for all patients. Laboratory investigations in
the form of complete blood count (CBC), erythrocyte sedimen-
tation rate (ESR), rheumatoid factor (RF) and anti-cyclic cit-
rullinated peptide (anti-CCP) were performed. Disease activity
score, in 28 joints (DAS-28),16 was calculated. None of the
patients received any biologic agent before and those receiving
corticosteroids for the last 6 months or receiving any other
combination therapy were also excluded. None of the patients
had any associated other rheumatic disease or chronic inﬂam-
matory disease affecting other systems. Informed consents
were taken from the patients and the study was approved by
the local ethics committee and has been carried out in accor-
dance with the declaration of Helsinki.
2.2. Determination of serum BAFF level
All sera were preabsorbed with protein A (Amersham Biosci-
ences, Piscataway, NJ, USA) to deplete Ig. Serum BAFF levels
were analyzed by Enzyme Linked Immunosorbent Assay
(ELISA) using commercially available kits according to the
manufacturer’s protocol (Quantikine; R&D System, Minneap-
olis, MN, USA).
2.3. Statistical analysis
The data were collected, tabulated and analyzed by SPSS
package version 15 (SPSS corporation, USA). Data were sum-
marized as mean ± SD. Mann–Whitney test was used for
comparative analysis of 2 quantitative data. Non-parametric
analysis of variance (Kruskall–Wallis) was used for compari-
son of more than two groups; Spearman’s correlation analysis
was used for detection of the relation between 2 variables.
Logistic regression analysis was applied to detect the predic-
tors for the elevated BAFF level. Results were considered
signiﬁcant at p< 0.05.
3. Results
The mean age of the RA patients (36.08 ± 6.25 years) was
comparable with that of the control (37.23 ± 6.95 years,
p= 0.72).In the RA patients, the ESR was signiﬁcantly higher
(56.29 ± 18.7 mm/1st h) and the hemoglobin content was
lower (11.25 ± 1.52 g/dl) compared to the control
(25.27 ± 11.22 mm/1st h and 12.91 ± 1.26 g/dl) (p< 0.001
in both comparisons). The WBC and platelet counts werecomparable between patients (6.39 ± 2.14 · 103/ml and
316.16 ± 76.33 · 103/ml) and control (6.78 ± 2.55 · 103/ml
and 290.37 ± 68.57 · 103/ml, p= 0.45 and p= 0.09, respec-
tively). The serum BAFF level was signiﬁcantly higher in the
RA patients (1.82 ± 0.91 ng/ml) compared to the control
(0.71 ± 0.33 ng/ml) (p< 0.001).
There was a signiﬁcantly lower BAFF and disease activity
in RA patients receiving DMARDs (1.55 ± 0.73 ng/ml and
3.08 ± 0.73) compared to the newly diagnosed cases
(2.36 ± 1.02 ng/ml and 3.46 ± 0.82) (p< 0.001 and
p= 0.036, respectively). Also there was a signiﬁcantly older
age (37.33 ± 6.42 years) and longer disease duration
(10.58 ± 3.64 years) in those on treatment compared to those
not (33.6 ± 5.14 years and 1.78 ± 1.32 years; p= 0.004 and
p< 0.001, respectively).
Comparison of the demographic and clinical features, dis-
ease activity, laboratory investigations and serum BAFF level
of the RA patients on HCQ+MTX with those on
LFN+MTX are shown in Table 1.
Patients on HCQ+MTX had a signiﬁcantly higher BAFF
(1.29 ± 0.51 ng/ml) and DAS28 (2.99 ± 0.71 years) than
those not on any therapy (2.36 ± 1.02 ng/ml and
3.46 ± 0.82 years, p< 0.001 and p= 0.017, respectively).
Those on LFN+MTX had a non-signiﬁcant rise in the
BAFF (1.94 ± 0.85 ng/ml) and DAS28 (3.21 ± 0.75) com-
pared to those not receiving any therapy (2.36 ± 1.02 and
3.46 ± 0.82, p= 0.1 and p= 0.25, respectively). Serum
BAFF levels in different study groups including RA patients
on HCQ+MTX, on LFN+MTX, not receiving any ther-
apy and the control, are shown in Fig. 1. Furthermore, the
hemoglobin content signiﬁcantly reduced in those not receiv-
ing any therapy (10.91 ± 1.46 g/dl vs 11.8 ± 1.42 g/dl,
p= 0.03).
Correlation tests of serum BAFF with demographic fea-
tures, MTX dose, disease activity and laboratory investiga-
tions are presented in Table 2.
Correlation of the serum BAFF level and the DAS28 in the
RA patients is shown in Fig. 2. The BAFF signiﬁcantly corre-
lated with DAS28 in those on DMARDs: (HCQ+MTX:
r= 0.37, p= 0.026 and LFN+MTX: r= 0.45, p= 0.028)
and in those awaiting a therapeutic regimen (r= 0.56,
p= 0.001).
A logistic regression analysis revealed that only DAS28 and
MTX dose would highly inﬂuence the serum BAFF level
(p= 0.015 and p= 0.001, respectively) among other indepen-
dent factors including the age, disease duration and presence
of anti-CCP.4. Discussion
In the present study the serum BAFF level was signiﬁcantly
higher in the RA patients compared to the control. It was even
higher in the newly diagnosed RA patients who had a higher
disease activity and shorter disease duration. This was similar
to the ﬁndings in other studies1,6,17–20 that observed the in-
creased levels and reported the important roles played by it
in RA. The increased levels of BAFF in very early RA patients
suggest that B-cell activation and the development of autoreac-
tive B-cell responses might be crucial in early phases of the
disease.19–21
Table 1 Comparison of the demographic and clinical features, disease activity, laboratory investigations and serum BAFF level of
rheumatoid arthritis patients on HCQ+MTX with those on LFN+MTX.
Variable
(mean ± SD)
RA patients on DMARDs (60) p value
HCQ+MTX (36) LFN+MTX (24)
Age (years) 38.33 ± 6.76 35.81 ± 5.68 0.13
Disease duration (years) 10.94 ± 3.93 10.04 ± 3.17 0.33
DAS28 2.99 ± 0.71 3.21 ± 0.75 0.28
Methotrexate (mg/week) 11.81 ± 4.21 15.94 ± 3.11 <0.001
ESR (mm/1st h) 53 + 19.57 54.63 ± 16.72 0.73
Hemoglobin (g/ml) 11.16 ± 1.58 11.8 ± 1.42 0.11
WBC (·103/ml) 6.28 ± 2.2 6.83 ± 2.37 0.37
Platelets (·103/ml) 302.06 ± 72.97 308.25 ± 68.07 0.74
RF positivity no. (%) 31(86.11) 21 (87.5) 0.88
Anti-CCP positivity no. (%) 26 (72.22) 19 (79.17) 0.54
Serum BAFF level (ng/ml) 1.29 ± 0.51 1.94 ± 0.85 0.002
DMARD: Disease modifying anti-rheumatic drug, DAS28: Disease activity score in 28 joints, ESR: Erythrocyte sedimentation rate, WBC:
White blood cells, RF: Rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide, BAFF: B-cell activating factor belonging to the tumor
necrosis factor family.
Figure 1 Serum BAFF level in different study groups including
RA patients on HCQ+MTX, on LFN+MTX, not receiving
any therapy and the control. BAFF: B-cell activating factor
belonging to the tumor necrosis factor family, HCQ: hydroxy-
chloroquine, MTX: methotrexate, LFN: leﬂunomide.
Table 2 Correlation of serum BAFF with demographic
features, MTX dose, disease activity and laboratory
investigations.
Variable BAFF (ng/ml)
r p
Age (years) 0.2 0.06
Disease duration (years) 0.18 0.09
DAS28 0.504 <0.001
Methotrexate (mg/week) 0.512 <0.001
ESR (mm/1st h) 0.03 0.8
Hemoglobin (g/ml) 0.11 0.31
WBC (·103/ml) 0.02 0.87
Platelets (·103/ml) 0.11 0.29
RF positivity no. (%) 0.16 0.12
Anti-CCP positivity no. (%) 0.24 0.02
DAS28: Disease activity score in 28 joints, ESR: Erythrocyte sed-
imentation rate, WBC: White blood cells, RF: Rheumatoid factor,
anti-CCP: anti-cyclic citrullinated peptide, BAFF: B-cell activating
factor belonging to the tumor necrosis factor family.
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opment of autoimmunity. Focus on BAFF and autoimmunity,
driven by pharmaceutical successes with the recent approval of
a novel targeted therapy Belimumab, has relegated other po-
tential roles of BAFF to the background. Far from being
SLE-speciﬁc, the BAFF system has a much broader relevance
in infection, cancer and allergy.22
B cells play critical roles in RA pathogenesis as they are the
source of RFs and anti-CCP autoantibodies, which contribute
to IC formation in the joints. These cells are also efﬁcient anti-
gen-presenting cells and contribute to T-cell activation throughexpression of co-stimulatory molecules. B cells simultaneously
respond and produce chemokines and cytokines that promote
leukocyte inﬁltration into the joints, formation of ectopic lym-
phoid structures, angiogenesis and synovial hyperplasia.19
In the present study, a signiﬁcant correlation was present
between the serum BAFF level and the DAS28 in the RA pa-
tients. This would support the suggestion of considering BAFF
as a biomarker of disease activity in RA. In agreement to this
ﬁnding, other studies found similar signiﬁcant correlation of
BAFF with DAS28 in RA patients.1,23 On the other hand,
the study of Gottenberg et al.21 found markers of B-cell activa-
tion, except BAFF, were associated with disease activity, RF
and anti-CCP secretion in early RA. In a previous study on
juvenile idiopathic arthritis cases, BAFF correlated only with
the juvenile arthritis disease activity score in 27 joints (JA-
DAS-27) and was signiﬁcantly higher in oligoarticular onset
patients with uveitis.8
Despite long-term usage of anti-inﬂammatory drugs in
RA patients, increased BAFF, might suggest a propensity to
overproduce these inﬂammatory mediators but whether this re-
Figure 2 Correlation of the serum BAFF level and the DAS28 in all RA patients. BAFF: B-cell activating factor belonging to the tumor
necrosis factor family, DAS28: Disease activity score in 28 joints.
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moot.24
In this study, the BAFF level signiﬁcantly correlated with
the anti-CCP positivity in the RA patients but did not with
the RF. In a different study, BAFF correlated with the titers
of IgM RF and anti-cyclic citrullinated peptide autoanti-
body,17 while in another recent study, the BAFF level had
no correlation with the titers of RF and anti-CCP antibodies.
The BAFF level in RA patients receiving MTX combina-
tion therapy was signiﬁcantly lower than in those still not
receiving any treatment. In a follow-up study on methotrex-
ate-treated early RA patients, reduced levels of BAFF, with
parallel improvement in clinical activity and decrease in auto-
antibody titers were revealed.17
Patients of the present study on HCQ plus MTX combina-
tion therapy showed a signiﬁcantly reduced serum BAFF level
compared to those receiving LFN or those still not receiving
any therapy. It has been reported in patients with primary Sjo¨-
gren’s syndrome (pSS) that the salivary and serum BAFF lev-
els were signiﬁcantly lowered when treated with HCQ.25 Not
only did HCQ alleviate symptoms and signs of dry eye but
decreased tear ﬂuid BAFF levels.26 On the contrary, no signif-
icant change in serum BAFF level was observed in another
study on pSS patients treated with low-dose corticosteroids
or HCQ.27 Hydroxychloroquine is still considered a standard
drug, provided its use is optimized.28
There was a tendency to a reduced the BAFF level in RA
patients on LFN plus MTX compared to those not receiving
any medication. Leﬂunomide is an immunosuppressive drug
that exerts its activity by inhibiting de novo pyrimidine synthe-
sis by blocking the mitochondrial enzyme dihydro-orotate de
hydrogenase (DHODH), and possibly, inhibition of tyrosine
kinase activity.29 It has been found to inhibit both T-cell and
B-cell function30 and a dose-dependent protective effect on
autoantibodies production in tolerized mice was presented.29
Consistent with the role of DHODH in lymphocyte prolifera-tion, leﬂunomide has proven effective and was approved for
the treatment of RA.31 Signiﬁcant beneﬁts of short-term
leﬂunomide therapy were associated with functional suppres-
sion of peripheral B lymphocytes.32
One of the main goals in management is to optimize the
treatment for rheumatoid arthritis patients. Nevertheless, rig-
orous evaluation of the risk/beneﬁt ratio of new drugs and
of their most appropriate place in the therapeutic strategy is
indispensable.28
Targeting BAFF might be a promising and useful therapeu-
tic strategy to treat B-cell related autoimmune diseases5 and in
early RA.19,21 A good clinical response to TNF antagonist
therapy in RA patients is associated with a decline in BAFF
levels. Increased BAFF expression in affected joints may con-
tribute to ongoing disease activity, and reduction of such
expression may help promote a favorable clinical response to
the anti-TNF therapy.18
Rituximab results appear very interesting and other anti-
BAFF drugs should also be evaluated.28 Tabalumab, a human
monoclonal antibody that neutralizes membrane-bound and
soluble BAFF in RA patients with inadequate response to
MTX, showed a dose-response improvement in disease activity
assessed by DAS2833 and a comparable safety proﬁle to those
receiving placebo with MTX.34 Belimumab is another fully hu-
man monoclonal antibody that inhibits BAFF and it is being
developed for the treatment of RA. It was well tolerated over
24 weeks and signiﬁcantly increased the American College of
Rheumatology (ACR)20 responses, especially in patients with
high disease activity, positive RF, no anti-TNF treatment
experience and those who had failed MTX therapy. However,
belimumab failed to demonstrate signiﬁcantly improved
ACR50 and ACR70 responses in the single Phase II clinical
trial of RA. Expert opinion suggested that its clinical efﬁcacy
needs to be further investigated in future clinical trials and that
careful patient selection may be necessary to achieve optimal
clinical outcomes in RA.6
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LAR response’’ in RA and should be identiﬁed as a possible
biomarker of response in patients undergoing the B cell deple-
tion therapy (BCDT).35
It is important that hydroxychloroquine is not missed from
the new therapeutic armamentarium targeting B-cells and
further studies combining HCQ to anti-B cells might improve
the outcome of the disease. Further longitudinal studies on a
larger number of patients and including those on different
new biologic agents would be interesting to conﬁrm the present
results and to throw light on the importance of considering the
classic treatment regimens for RA in combination with the
biologics when ﬁrst line medications fail to achieve a satisfac-
tory response. The BAFF should be considered as a therapeu-
tic target among the many options of RA treatment.
5. Conclusions
In conclusion, the elevated level of BAFF in RA has been con-
ﬁrmed with a notable relation to disease activity making it a
promising marker. The beneﬁcial effect of HCQ in dampening
the serum BAFF level throws light on the importance of
considering it in combination among the newly developed
biologics that also target B-cells.
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